Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI

NCT05613426 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

330

Enrollment

OTHER

Sponsor class

Conditions

ST Elevation Myocardial Infarction (STEMI)

Interventions

DRUG: Rosuvastatin 20 mg
DRUG: Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]

Sponsor

Henan Institute of Cardiovascular Epidemiology